Efficacy and tolerability of current treatments for hormone-refractory prostate cancer patients with visceral metastases

Oruc Z., Kaplan M. A., Karaagac M., Ozyurt N., TATLI A. M., Kaya A. O., ...Daha Fazla

FUTURE ONCOLOGY, cilt.17, sa.13, ss.1611-1624, 2021 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 13
  • Basım Tarihi: 2021
  • Doi Numarası: 10.2217/fon-2020-1032
  • Dergi Adı: FUTURE ONCOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.1611-1624
  • Anahtar Kelimeler: hormone-refractory disease, prostate cancer, visceral metastasis
  • Akdeniz Üniversitesi Adresli: Evet

Özet

Aim: To assess the efficacy and tolerability of the first-line treatment options for hormone-refractory prostate cancer patients with visceral metastases. Materials and methods: The records of 191 patients diagnosed with hormone-refractory prostate cancer with visceral metastases were analyzed retrospectively. Results: Docetaxel was administered to 61.2% (n = 117), abiraterone to 14.2% (n = 27) and enzalutamide to 9.4% (n = 18) as the first-line treatment. The median survival of the patients receiving docetaxel, abiraterone and enzalutamide as the first-line treatment during the hormone-refractory period was 15 (95% Cl: 12.9-17) months, 6 (95% Cl: 1.8-10.1) months and 11 (95% Cl: 0.9-23.1) months (p = 0.038), respectively. Conclusion: The present study established a statistically significant difference in favor of docetaxel in terms of overall survival and progression-free survival.